got research?

405.773-6613/405 636-7951

▶ICIO SMC study description May 2025

STUDY NAME	DZ SITE	STUDY Description	DESIGN		# PTS
NRG-GI008	Stage IIA Colon Cancer Natera Kits provided by the Study	*Colon Adjuvant Chemotherapy based on Evaluation of Residucal Disease (Circulate-US)* ***Cohort B** – ctDNA positive* ***Stratification** – Intended Chemo (5 FU vs. Xeloda)* ***Randomization*** ***Arm 3 – mFOLFOX 6 or CAPOX for 6 months*** ***A4m 4 – mFOLFIRINOX for 6 months***	**Cohort A** **ctDNA-neg** **Stratification-Stage IIIA vs IIIB** **Intended chemo (5FU vs. Xeloda)**	**After Randomization:** **Arm 1** FOLFOX6 for 3 – 6 months or CAPOX for 3 months. **Arm 2 –** Surveillance	
S2302	NSCLC	A Prospective Randomized Study of Ramucirumab + Pemrbolizumab vs. standard of care for participants previously treated with Immnotherapy for Stage IV or recurrent NSCLC	**Arm A:** Investigator's SOC	**Arm B:** Ramucirumab + Pembrolizumab	
A081801	NSCLC	*NSCLC: ALCHEMIST-IO* ***Must have EGRF, ALK, PD-LI IHC local testing with no identified arrangements. Must have completely resected dz IB (>/= 4cm), II or IIIA NSCLC with negative margins Patients with N2 Disease completely resected are eligible. However, patients with known N2 dz prior to surgery or ineligible.***	**Arm A:** 4 Cycles of Platinum doublet With Observation afterwards	**Arm B:** 4 Cycles of Platinum doublet with 17 cycles of Keytruda **Amr C**: 4 Cycles of Platinum doublet + Keytruda with 13 more cycles of Keytruda	1
EA5182	NSCLC	Randomized Phase III Study of Combination AZD9291 (Osimertinib) and Bevacizumab vs. AZD9291 (Osimertinib) Alone as First Line Treatment for Patients with Metastatic EGRR-Mutant Non Small Cell Lung Cancer (NSCLC)	**Arm A:** Osimertinib 80 mg PO Daily	**Amr B:** Osimertinib 80 mg Daily; Bevacizumab 15 mg kg IV every 3 weeks	
S2303	Gastric and Esophageal Adenocarcinoma	"Randomized Phase II/III Trial of 2nd Line Nivolumab + Paclitaxel + Ramucirumab versus Paclitaxel + Ramucirumab in Patients with PD-L1 CPS ≥ 1 Advanced Gastric and Esophageal Adenocarcinoma (PARAMUNE)."	**Arm 1:** Nivolumab, Paclitaxel, Ramucirumab	**Arm 2:** Paclitaxel, Ramucirumab	
CVAY736I12301	Novartis	A phase III, randomized, double-blind study of ianalumab (VAY736) vs. placebo in addition to first-line corticosteroids in primary immune thrombocytopenia	**Arm A: Ianalumab 3mg/kg every 4 weeks (4 doses in total) + corticosteroids daily**	**Arm B: Ianalumab 9mg/kg every 4 weeks + corticosteroids daily** **Arm C: Placebo every 4 weeks**	
ARGX-113-2402	ARGENX	A Phase 3, Multicenter, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Arm Study Followed by an Open-Label Arm toEvaluate the Efficacy and Safety of Efgartigimod IV in Adult Participants With Primary Immune Thrombocytopenia	**Arm A: Efgartigimod IV 10 mg/kg** **Arm B: Placebo**	**After 24 weeks patients will receive Efgartigimod IV 10 mg/kg for 52 weeks**	